Civeo Rebounds Following Monday’s Plunge

With the S&P 500 down -0.71% midday, this Wednesday is starting off slow on Wall Street. A handful of companies, however, are making strong gains. Here’s a look at the four top-gaining billionaire stock picks at midday today: Civeo Corp (NYSE:CVEO), GlycoMimetics Inc (NASDAQ:GLYC), Babcock & Wilcox Co (NYSE:BWC) and Sarepta Therapeutics Inc (NASDAQ:SRPT).

Sign Up For Our Free Newsletter

This Tiger Cub Giant Is Betting On Banks And Tech Stocks In The Recovery

D1 CapitalThe first two months of the third quarter were the best months for D1 Capital Partners' public portfolio since inception, that's according to a copy of the firm's August update, which ValueWalk has been able to review. Q2 2020 hedge fund letters, conferences and more According to the update, D1's public portfolio returned 20.1% gross Read More

Civeo Corp (NYSE:CVEO) reached midday up +8.1%, rebounding a bit after tanking on Monday. The Oil States International spin-off abandoned plans to become an REIT early in the week, instead opting to redomicile to Canada for tax purposes. With the purchase of 6.15 million shares, David Einhorn initiated a position in the company in Q2.

GlycoMimetics Inc (NASDAQ:GLYC) climbed +7.62% early in the day this Wednesday. Yesterday, shares plunged after the company’s announcement of a delay in one of its studies. The clinical stage biotech company, a new Q2 pick for billionaire investor George Soros, is down -17.02% year-to-date.


Babcock & Wilcox Co (NYSE:BWC) got a +7.22% boost this morning on the heels of news that it is considering splitting its power-generation and government and nuclear operations businesses into two separate companies. In David Einhorn’s investment portfolio since the third quarter of 2012, BWC has had a rough go in 2014, its price declining -13.31% YTD.

Also getting a strong start to the day is Sarepta Therapeutics Inc (NASDAQ:SRPT), the share price of which surged +5.21%. The explanation: news yesterday that the first case of the Ebola virus has reached the United States. Sarepta has been developing a drug for the virus – company CEO Chris Garabedian said on CNBC today that it has enough stock to handle up to 100 cases. George Soros has held a position in SRPT since the third quarter of 2012.

Sign Up For Our Free Newsletter